VSPharmTech
Monday, June 03, 2024
Oncology
Company Presentation Theater 1
VSPharmTech is a clinical stage biotechnology company established in 2018 with the goal of advancing life-saving drug development. We pursue safe and effective drug development for cancer patients focusing on the area of high unmet medical needs. Our portfolio includes a radiosensitizer VS-101 to be used in combination with radiation therapy, a chemosensitizer VS-301, VS-501 which inhibits cancer metastasis. Phase 2 clinical trial for HNC in the US embarked with MD Anderson Cancer Center while Phase 1 clinical trial has been underway in Korea. Expanding indications of VS-101 is planned by IND submissions for breast cancer and pancreatic cancer in the US.
Thanks to the progress in drug development, we were honored to be designated as the Baby Unicorn and Excellent company in R&D by the Korean government while successfully completing the Series B round in 2023.
As multinational clinical trials are prepared, we are poised to venture into the global market to showcase our technology.
Company Website:
http://www.vspharmtech.com
Lead Product in Development:
3 promising investigational drugs are under development: VS-101 and VS-301 enhance the efficacy of radiotherapy and chemotherapy, while VS-501 inhibits cancer metastasis.
VS-101 is a potent oral radiosensitizer that enhances the sensitivity of cancer cells to radiation when combined with radiotherapy. VS-101 causes DNA damage, directly and indirectly enhances ROS generation by irradiation, and binds to IAP to induce apoptosis. Ultimately it enhances the efficacy of radiation therapy and enables us to use low doses of radiation. Phase 2 clinical trial in the US has embarked while Phase 1 clinical trial in Korea has been underway.
Company HQ City
Seoul
Company HQ State
Nowon-gu
Company HQ Country
Korea, Republic of
CEO/Top Company Official
ShinYoung Park
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())